Obianda, Anna Mae T.

HRN: 20-40-41  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/24/2022
CEFUROXIME 1.5GM (VIAL)
05/24/2022
05/24/2022
IVT
1.5G
LD
For CS
Waiting Final Action 
05/24/2022
CEFUROXIME 750MG (VIAL)
05/24/2022
05/31/2022
IVT
750mg
Q8
For OR
05/24/2022
CEFUROXIME 500MG (TAB)
05/24/2022
05/31/2022
ORAL
500mg
Q12
Thick MSAF
Waiting Final Action 
05/24/2022
METRONIDAZOLE 500MG (TAB)
05/24/2022
05/31/2022
ORAL
500mg
Q8
Thickly MSAF
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: